Javascript must be enabled to continue!
A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane
View through CrossRef
Purpose. To compare the efficacy and safety of suprachoroidal and intravitreal injection of triamcinolone acetonide in pseudophakic patients with refractory diabetic macular edema (DME) due to epiretinal membrane (ERM). Study Design. This study is a randomized clinical trial (RCT). Participants. Twenty-three nonvitrectomized pseudophakic eyes of 23 subjects (9 M and 14 F with mean age: 54.8 years) with refractory DME due to ERM. Methods. The eyes were randomized to suprachoroidal triamcinolone acetonide injection 4 mg/0.1 ml (SCTA) (n = 13 eyes) or intravitreal triamcinolone acetonide 4 mg/0.1 ml (IVTA) (n = 10 eyes) and were evaluated at baseline and 1 and 3 months after injection to assess outcome measures. Main Outcome Measures. Changes in best-corrected visual acuity (BCVA) (primary outcome), central foveal thickness (CFT) by optical coherence tomography (OCT), and intraocular pressure (IOP) measurement (secondary). Results. Baseline median BCVA (logMAR) was 1.0 (range 0.8–1.0) in both groups, improved within the SCTA group to 0.8 on the 1st and 3rd months, while in the IVTA group, median BCVA changed to 0.8 and 0.9 on the 1st and 3rd months, respectively. No significant differences were noted between groups regarding BCVA at baseline (
P
=
0.927
), and 1st (
P
=
0.605
) and 3rd months (
P
=
0.313
). Regarding mean CFT, no significant differences were observed at baseline (
P
=
0.353
) and at the first month (
P
=
0.214
) between both groups, while at the third month, CFT was significantly higher in the IVTA group (385 um) than in the SCTA group (323 um) (
P
=
0.028
). Mean IOP was significantly higher in the IVTA group (15 mmHg) on 1st month than in the SCTA group (12 mmHg) (
P
=
0.011
); after 3rd month, IOP was significantly higher within the IVTA group (18 mmHg) than SCTA (14 mmHg) (
P
=
0.028
). No significant difference was noted between both groups at baseline IOP (
P
=
0.435
). Conclusions. Both SCTA and IVTA are effective in reduction of CFT and improvement of patients’ visual acuity, but with a higher recurrence rate and rise in IOP after IVTA when compared to SCTA. Both treatments have temporary effects with the possibility of recurrence of DME and the need for retreatment.
Title: A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane
Description:
Purpose.
To compare the efficacy and safety of suprachoroidal and intravitreal injection of triamcinolone acetonide in pseudophakic patients with refractory diabetic macular edema (DME) due to epiretinal membrane (ERM).
Study Design.
This study is a randomized clinical trial (RCT).
Participants.
Twenty-three nonvitrectomized pseudophakic eyes of 23 subjects (9 M and 14 F with mean age: 54.
8 years) with refractory DME due to ERM.
Methods.
The eyes were randomized to suprachoroidal triamcinolone acetonide injection 4 mg/0.
1 ml (SCTA) (n = 13 eyes) or intravitreal triamcinolone acetonide 4 mg/0.
1 ml (IVTA) (n = 10 eyes) and were evaluated at baseline and 1 and 3 months after injection to assess outcome measures.
Main Outcome Measures.
Changes in best-corrected visual acuity (BCVA) (primary outcome), central foveal thickness (CFT) by optical coherence tomography (OCT), and intraocular pressure (IOP) measurement (secondary).
Results.
Baseline median BCVA (logMAR) was 1.
0 (range 0.
8–1.
0) in both groups, improved within the SCTA group to 0.
8 on the 1st and 3rd months, while in the IVTA group, median BCVA changed to 0.
8 and 0.
9 on the 1st and 3rd months, respectively.
No significant differences were noted between groups regarding BCVA at baseline (
P
=
0.
927
), and 1st (
P
=
0.
605
) and 3rd months (
P
=
0.
313
).
Regarding mean CFT, no significant differences were observed at baseline (
P
=
0.
353
) and at the first month (
P
=
0.
214
) between both groups, while at the third month, CFT was significantly higher in the IVTA group (385 um) than in the SCTA group (323 um) (
P
=
0.
028
).
Mean IOP was significantly higher in the IVTA group (15 mmHg) on 1st month than in the SCTA group (12 mmHg) (
P
=
0.
011
); after 3rd month, IOP was significantly higher within the IVTA group (18 mmHg) than SCTA (14 mmHg) (
P
=
0.
028
).
No significant difference was noted between both groups at baseline IOP (
P
=
0.
435
).
Conclusions.
Both SCTA and IVTA are effective in reduction of CFT and improvement of patients’ visual acuity, but with a higher recurrence rate and rise in IOP after IVTA when compared to SCTA.
Both treatments have temporary effects with the possibility of recurrence of DME and the need for retreatment.
Related Results
<b>COMPARISON OF EFFICACY OF 4mg VERSUS 2mg SUPRACHOROIDAL INJECTION TRIAMCINOLONE ACETONIDE IN THE TREATMENT OF DIABETIC MACULAR EDEMA</b>
<b>COMPARISON OF EFFICACY OF 4mg VERSUS 2mg SUPRACHOROIDAL INJECTION TRIAMCINOLONE ACETONIDE IN THE TREATMENT OF DIABETIC MACULAR EDEMA</b>
Background: One of the primary causes of blindness in working-age diabetics worldwide is macular edema, which is a consequence of diabetic retinopathy. In individuals with diabetes...
Suprachoroidal injection of triamcinolone acetonide for management of resistant diabetic macular edema (SCTA): original article
Suprachoroidal injection of triamcinolone acetonide for management of resistant diabetic macular edema (SCTA): original article
Objective: To estimate the effects and safety of suprachoroidal triamcinolone acetonide injections in treating patients with resistant diabetic macular oedema.
Methods: The quasi-e...
A combination of suprachoroidal injection of triamcinolone using a custom-made needle and intravitreal Ziv-aflibercept every eight weeks to manage naïve/denovo central DME: a single-center retrospective case series
A combination of suprachoroidal injection of triamcinolone using a custom-made needle and intravitreal Ziv-aflibercept every eight weeks to manage naïve/denovo central DME: a single-center retrospective case series
Abstract
Background
Previous studies have shown promising effects of combining intravitreal bevacizumab and suprachoroidal injection of triamcinolon...
Anatomical and Functional Outcome of Suprachoroidal Triamcinolone Injection in Patients of Refractive Diabetic Macular Oedema
Anatomical and Functional Outcome of Suprachoroidal Triamcinolone Injection in Patients of Refractive Diabetic Macular Oedema
The most frequent cause of central vision loss in people with diabetes with diabetic retinopathy is diabetic macular edema (DME). Recently, there has been a greater interest in inv...
Alterations in Central Retinal Sensitivity after Intravitreal Triamcinolone Injection for Diffuse Diabetic Macular Edema
Alterations in Central Retinal Sensitivity after Intravitreal Triamcinolone Injection for Diffuse Diabetic Macular Edema
Purpose
To evaluate alterations in central retinal sensitivity following intravitreal triamcinolone injection in patients with diffuse diabetic macular edema th...
Suprachoroidal Injection of Triamcinolone Acetonide: Advancing Treatment for Resistant Diabetic Macular Edema
Suprachoroidal Injection of Triamcinolone Acetonide: Advancing Treatment for Resistant Diabetic Macular Edema
Purpose: To evaluate the effectiveness and safety of suprachoroidal triamcinolone acetonide (SCTA) in managing treatment-resistant diabetic macular edema (DME) over a 6-month peri...
Immunohistochemical study of spatial relationships in idiopathic epiretinal membrane components
Immunohistochemical study of spatial relationships in idiopathic epiretinal membrane components
Introduction. Idiopathic epiretinal membrane is a formation of a fibrous cellular tissue in the macula. To our understanding there is no data on the interaction of epiretinal membr...
TO STUDY THE ROLE OF SUPRACHOROIDAL INJECTION TRIAMCINOLONE IN NON-INFECTIOUS UVEITIS
TO STUDY THE ROLE OF SUPRACHOROIDAL INJECTION TRIAMCINOLONE IN NON-INFECTIOUS UVEITIS
Purpose:- The research was done to study the role of Suprachoroidal injection of Triamcinolone in patients of newly diagnosed non-infectious
anterior, non-infectious intermediate a...

